A deep dive into four thyroglobulin immunoassays from analytical perspective

Backgrounds Serum thyroglobulin immunometric assays (sTg) are crucial for monitoring differentiated thyroid cancer (DTC) treatment. However, challenges such as anti-thyroglobulin autoantibodies (TgAb) and assay variability hinder evaluations. This study assessed four sTg methods—three second-generation (Architect, Access, Elecsys) and one first-generation (Immulite)—following Clinical and Laboratory Standards Institute (CLSI) and American Thyroid Association (ATA) guidelines.